• Drug Discov Today. 2019;24:624-628. Advancing nonclinical innovation and safety in pharmaceutical testing. Baker EJ, Beck NA, Berg EL, Clayton-Jeter HD, Chandrasekera PC, Curley JL, Donzanti BA, Ewart LC, Gunther JM, Kenna JG, LeCluyse EL, Liebman MN, Pugh CL, Watkins PB, Sullivan KM. PubMed
  • Clin Pharmacol Ther. 2018;104:916-932. Can Bile Salt Export Pump inhibition testing in drug discovery and development reduce liver injury risk? An International Transporter Consortium perspective. Kenna JG, Taskar KS, Battista C, Bourdet DL, Brouwer KLR, Brouwer KR, Dai D, Funk C, Hafey MJ, Lai Y, Maher J, Pak YA, Pedersen JM, Polli JW, Rodrigues AD, Watkins PB, Yang K, Yucha RW1; International Transporter Consortium. PubMed
  • Kenna, JG, Waterton, JC, Baudy, A, Galetin, A, Hines, CDG, Hockings, P, Patel, M, Scotcher, D, Sourbron, S, Ziemian, S & Schuetz, G 2018, Noninvasive preclinical and clinical imaging of liver transporter function relevant to drug-induced liver injury. in Drug-Induced Liver Toxicity. Methods in Pharmacology and Toxicology, no. 9781493976768, Humana Press, Inc., New York, NY, pp. 627-651. Web
  • Drug Metab Dispos. 2018;46:1658-1669. Do in vitro assays predict drug candidate idiosyncratic drug-induced liver injury risk? Kenna JG, Uetrecht J. PubMed
  • Toxicol Res (Camb). 2016;6:81-88. Improved hepatic physiology in hepatic cytochrome P450 reductase null (HRN™) mice dosed orally with fenclozic acid. Akingbasote JA, Foster AJ, Jones HB, David R, Gooderham NJ, Wilson ID, Kenna JG. PubMed
  • J Pharmacol Exp Ther. 2015;352:281-90. Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists. Kenna JG, Stahl SH, Eakins JA, Foster AJ, Andersson LC, Bergare J, Billger M, Elebring M, Elmore CS, Thompson RA.  PubMed
  • Toxicol Sci. 2015;148:48-59. Quantification of drug-induced inhibition of canalicular Cholyl-l-Lysyl-Fluorescein excretion from hepatocytes by high content cell imaging.  Barber JA, Stahl SH, Summers C, Barrett G, Park BK, Foster JR, Kenna JG. PubMed
  • Curr Protoc Toxicol. 2014;61:23.7.1-15. Current concepts in drug-induced Bile Salt Export Pump (BSEP) interference. Kenna JG. PubMed
  • Toxicol In Vitro. 2014;28:171-81. Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes. Garside H, Marcoe KF, Chesnut-Speelman J, Foster AJ, Muthas D, Kenna JG, Warrior U, Bowes J, Baumgartner J. PubMed
  • Toxicol Sci. 2014;137:189-211. A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. Gustafsson F, Foster AJ, Sarda S, Bridgland-Taylor MH, Kenna JG. PubMed
  • Integr Biol (Camb). 2013;5:877-88. Multiscale modelling approach combining a kinetic model of glutathione metabolism with PBPK models of paracetamol and the potential glutathione-depletion biomarkers ophthalmic acid and 5-oxoproline in humans and rats. Geenen S, Yates JW, Kenna JG, Bois FY, Wilson ID, Westerhoff HV. PubMed
  • Arch Toxicol. 2013;87:1569-79. In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid. Rodrigues AV, Rollison HE, Martin S, Sarda S, Schulz-Utermoehl T, Stahl S, Gustafsson F, Eakins J, Kenna JG, Wilson ID. PubMed
  • NMR Biomed. 2013;26:1258-70. Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibition. Ulloa JL, Stahl S, Yates J, Woodhouse N, Kenna JG, Jones HB, Waterton JC, Hockings PD. PubMed
  • Drug Metab Dispos. 2012;40:2332-41. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Warner DJ, Chen H, Cantin LD, Kenna JG, Stahl S, Walker CL, Noeske T. PubMed
  • Drug Metab Dispos. 2012;40:2054-8. Characterization of THLE-cytochrome P450 (P450) cell lines: gene expression background and relationship to P450-enzyme activity. Soltanpour Y, Hilgendorf C, Ahlström MM, Foster AJ, Kenna JG, Petersen A, Ungell AL. PubMed
  • Chem Res Toxicol. 2012;25:1616-32. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ, Dolgos H, Weaver R, Kenna JG. PubMed
  • Arch Toxicol. 2012;86:1251-71. Systems biology tools for toxicology. Geenen S, Taylor PN, Snoep JL, Wilson ID, Kenna JG, Westerhoff HV. PubMed
  • Expert Opin Drug Metab Toxicol. 2012;8:909-20. The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human. Andersson TB, Kanebratt KP, Kenna JG. PubMed
  • Xenobiotica. 2012;42:503-17. Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers. Schulz-Utermoehl T1, Sarda S, Foster JR, Jacobsen M, Kenna JG, Morikawa Y, Salmu J, Gross G, Wilson ID. PubMed
  • Drug Metab Dispos. 2012;40:130-8. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Dawson S, Stahl S, Paul N, Barber J, Kenna JG. PubMed
  • Toxicology. 2010;268:125-31. Cell based approaches for evaluation of drug-induced liver injury. Greer ML, Barber J, Eakins J, Kenna JG. PubMed
  • Drug Metab Rev. 2007;39:159-234. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Hewitt NJ1, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG. PubMed
  • Curr Opin Drug Discov Devel. 2004;7:86-99. Cellular models for ADMET predictions and evaluation of drug-drug interactions. Riley RJ, Kenna JG. PubMed


Manchester (United Kingdom)


Last update: October 2021